Literature DB >> 22005650

Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia.

Richard Champlin1.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22005650      PMCID： PMC4037318          DOI： 10.1016/j.bbmt.2011.10.009

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  17 in total

1.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.

Authors:  Hagop Kantarjian; Susan O'brien; Jorge Cortes; Francis Giles; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; William Wierda; Sherry Pierce; Jianqin Shan; Elihu Estey
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

2.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

3.  Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.

Authors:  B L Scott; B M Sandmaier; B Storer; M B Maris; M L Sorror; D G Maloney; T R Chauncey; R Storb; H J Deeg
Journal:  Leukemia       Date:  2006-01       Impact factor: 11.528

4.  Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Authors:  Elihu Estey; Marcos de Lima; Raoul Tibes; Sherry Pierce; Hagop Kantarjian; Richard Champlin; Sergio Giralt
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

5.  Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.

Authors:  Sudhir Tauro; Charles Craddock; Karl Peggs; Gulnaz Begum; Premini Mahendra; Gordon Cook; Judith Marsh; Donald Milligan; Anthony Goldstone; Ann Hunter; Asim Khwaja; Raj Chopra; Timothy Littlewood; Andrew Peniket; Anne Parker; Graham Jackson; Geoff Hale; Mark Cook; Nigel Russell; Stephen Mackinnon
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

6.  How does bone-marrow transplantation cure leukaemia?

Authors:  R P Gale; R E Champlin
Journal:  Lancet       Date:  1984-07-07       Impact factor: 79.321

Review 7.  Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases.

Authors:  E D Thomas
Journal:  J Clin Oncol       Date:  1983-09       Impact factor: 44.544

8.  Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.

Authors:  Olle Ringdén; Myriam Labopin; Gerhard Ehninger; Dietger Niederwieser; Richard Olsson; Nadezda Basara; Juergen Finke; Rainer Schwerdtfeger; Matthias Eder; Donald Bunjes; Norbert-Claude Gorin; Mohamad Mohty; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

9.  Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML).

Authors:  U Popat; H E Heslop; A Durett; R May; R A Krance; M K Brenner; G Carrum
Journal:  Bone Marrow Transplant       Date:  2006-03       Impact factor: 5.483

10.  Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

Authors:  Sherif S Farag; Kellie J Archer; Krzysztof Mrózek; Amy S Ruppert; Andrew J Carroll; James W Vardiman; Mark J Pettenati; Maria R Baer; Mazin B Qumsiyeh; Prasad R Koduru; Yi Ning; Robert J Mayer; Richard M Stone; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113
View more
  1 in total

1.  Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines.

Authors:  Lucia Mariano da Rocha Silla; Frederico Dulley; Rosaura Saboya; Eduardo Paton; Fabio Kerbauy; Adriano de Moraes Arantes; Nelson Hamerschlak
Journal:  Rev Bras Hematol Hemoter       Date:  2013
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.